Dr. Andrew Mason is a Professor of Medicine at the University of Alberta, where he is a Director of the Applied Genomics Core and Director of Research in the Division of Gastroenterology. He trained at King’s College London Liver Unit and was a Gastroenterology Fellow at Washington University, St. Louis, Missouri. He set up his research program at the Ochsner Clinic Foundation, New Orleans, Louisiana, in 1994, where he served as Medical Director of the Liver Transplant program. He relocated to Canada in 2002 as an Alberta Heritage Foundation for Medical Research Scholar and an Associate Professor of Medicine. Research interests: 1. Developing the Canadian Network for Autoimmune Liver Disease (CaNAL) to study demographic and prognostic features of PBC and AIH. 2. Clinical trials assessing anti-retroviral therapies for the treatment of primary biliary cholangitis. 3. Viral discovery in inflammatory bowel disease. 4. Betaretroviral induction of autoimmune biliary disease. 5. QuantiFERON assay development to detect immune responses to human betaretrovirus infection in patients with cancers and autoimmune liver disease.